Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Darzalex, Somatuline Grab Orphan Status for New Indications
February 23, 2018
- PMDA Announces Procedures for Using MID-NET
February 21, 2018
- Turning Point for Blood Products? Discussions on Basic Policy on Blood Law Moving Ahead
February 20, 2018
- Chugai Hemophilia Drug, Novel Zoster Vaccine Set for Approval Review on March 2
February 19, 2018
- Nobelpharma’s Sakigake-Designated Sirolimus Gel Up for MHLW Panel Review on March 1
February 19, 2018
- Harvoni Approved for Genotype 2 Hep C, Zytiga for Earlier Line
February 19, 2018
- PhRMA Wants Japan Put on “Priority Watch List” in USTR’s Trade Barrier Report
February 16, 2018
- MHLW OKs Authorized Generics for Aimix, Cravit IV, Takepron; June Listing Eyed
February 16, 2018
- 20 Gx Makers Flock to Aimix, Sawai Earns Approval for Tamiflu Copy for June Listing
February 16, 2018
- MHLW Launches Startup Support Project
February 16, 2018
- MHLW Looked at Balance and Made Major Revision Plans for Drug Pricing: Official
February 14, 2018
- Label Revisions Ordered for Gardenia Fruit Kampo Agents, Stocrin
February 14, 2018
- Japan Cabinet Adopts Bill to Require Generic Use for Welfare Recipients
February 13, 2018
- Payers Give High Marks for “Bold” Pricing Reform, but Not Happy with PMP
February 8, 2018
- Chuikyo Submits Recommendation for FY2018 Reimbursement Policy Reform, Drug Pricing Package Enshrined
February 8, 2018
- MHLW Notifies of Revisions of Ministerial Ordinances to Prevent Distribution of Counterfeit Drugs
February 7, 2018
- Japan’s 1st Herceptin Biosimilar Clears MHLW Panel, Now in Line for March Approval for Gastric Cancer
February 5, 2018
- MHLW Panel Backs “Sakigake” Influenza Drug; Possibility of Accelerated Approval and Listing Unclear
February 5, 2018
- MHLW Cautions on Hepatitis E Virus Infection due to Blood Products for Transfusion
February 2, 2018
- MHLW Panel Calls for Single-Product, Single-Price Transactions for Blood Products
February 2, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…